StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) company profile

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

About CRISPR Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a biopharmaceutical firm that develops gene-based medicines using CRISPR/Cas9 gene-editing technology. It operates across four primary areas: hemoglobinopathies, in vivo editing, CAR T cell therapies, and regenerative medicine. Its approved therapy, CASGEVY, co-developed with Vertex Pharmaceuticals, treats severe sickle cell disease and transfusion-dependent beta thalassemia. Other investigational candidates address cardiovascular conditions, autoimmune disorders, cancers, and Type 1 diabetes. Its end users are patients suffering from severe genetic, hematologic, oncologic, and metabolic diseases.

Its approved therapy is authorized in the United States, the European Union, Great Britain, Canada, Switzerland, and Middle Eastern countries including Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, and Kuwait. The company operates a manufacturing facility in Framingham, Massachusetts, to produce investigational cell therapies, and engages in clinical collaborations across the United States and Greater China. The provided text does not state the location of the company's headquarters.

Summary of the business section of CRISPR Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
CRISPR Therapeutics AG
Founded
2013
Headquarters
Zug, Switzerland
Address
Baarerstrasse 14
Phone
(617) 315-4600
Employees
393, Dec 31, 2024
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
V8
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
CRSP
Exchange
Nasdaq
IPO date
Oct 19, 2016
Shares outstanding
97M, Jul 31, 2026
Public float
$4.10B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1674416
CUSIP
H17182108
FIGI
BBG00DBBGRX1
Share class FIGI
BBG00DBBGRY0
EIN
47-3173478

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Samarth KulkarniChief Executive Officer, Director397,521
Sivakesava SakhamuriChief Technical Officer–
Naimish PatelChief Medical Officer19,357
James R. KasingerGeneral Counsel and Secretary95,857
Andrew Jacob SilverChief Financial Officer–
Raju PrasadChief Financial Officer14,815
Julianne BrunoChief Operating Officer17,632
Simeon GeorgeDirector2,054,249
Ali BehbahaniDirector345
John GreeneDirector7,000
Katherine A. HighDirector–
Douglas A. TrecoDirector22,000
Briggs MorrisonDirector5,209
Christian RommelDirector–
Sandesh MahatmeDirector–
Maria FardisDirector–
Harold Edward FlemingDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.68M$21.97M$3.60M$34$120
FY2024$33.18M$10.02M$5.59M$65$114
FY2023$12.32M$24.81M$2.61M$103$115
FY2022$20.73M$1.73M$3.86M$67$111
FY2021$17.04M-$27.37M$5.65M$124$125
FY2020$9.11M$76.94M$3.19M$251$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 19, 2016
Offer price
$14.00
Securities offered
4,000,000
Gross proceeds
$56.00M
Exchange
Nasdaq
First trading day
Oct 19, 2016
First-day close
$14.09+0.6%
Lock-up ends (est.)
Apr 17, 2017

“The initial public offering price is $14.00 per common share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2024, we had 393 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?